About Chariot Biosciences
Empowering Patients with Long-Term Therapeutic Solutions
Revolutionizing the delivery of therapeutics for chronic conditions
Chariot Biosciences is transforming the need for frequent biologic injections with a single injection synthetic biology solution – the Simmbiontm. Simmbions are engineered symbiotic microbes that deliver sustained-release therapeutics from a single subcutaneous injection. This technology harnesses the potential to overcome the leading causes of treatment failure, including complications and logistical challenges associated with chronic biologic drugs.
Chariot’s founders are alumni of the Immunology PhD program at the Johns Hopkins University School of Medicine (JHSOM). With over 30 years of cumulative experience in biopharma, the team has successfully exited multiple life science ventures and raised over $1 billion in capital.
Our Mission
Chariot Biosciences is transforming the treatment of chronic conditions through innovative cell therapies. Our pioneering Simmbion™ technology enables single injection sustained delivery of life-saving therapeutics, improving long-term outcomes. We strive to redefine the standard of care and enhance quality of life for patients worldwide.
Who We Are
We are a team of scientists, engineers, and medical professionals committed to advancing healthcare through cutting-edge technology. Our passion for improving patient quality of life drives our approach to simplifying complex treatment processes.
Our Vision
To empower patients by delivering consistent, effective care that fits seamlessly into daily life.
Meet Our Leadership Team
At Chariot Biosciences, our leadership team is composed of industry pioneers and visionaries dedicated to transforming the future of healthcare through innovation.
Derese Getnet PhD, D(ABMM)
US Army veteran. Prior Chief, Wound Infections Dept, Walter Reed Army Institute of Research. PhD In immunology and Molecular Biology from JHSOM
Samuel Collins PhD
Research Associate at JHSOM and US Army veteran who champions the nuances of pulmonary and critical care. SME in immunology, microbiology, and disease models. PhD In immunology and Molecular Biology from JHSOM
Greg Merril
Serial entrepreneur and founding CEO of Adaptive Phage Therapeutics (now BiomX – NYSE: PHGE). Mr. Merril has a track record of successfully navigating the regulatory landscape, manufacturing, and market strategy for novel living pharmacies.
Andrew Ross
Andrew Ross has over 25 years of finance experience, specializing in M&A due diligence, valuation, and financial modeling. He earned a BS from The Wharton School at the University of Pennsylvania.
Chariot Biosciences® is supported by
